Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer

► Early-stage papillary serous and clear cell endometrial cancer patients received HDR vaginal brachytherapy. ► A low-dose brachytherapy regimen of 24 Gy in 6 fractions resulted in a low rate of vaginal relapse. ► This low-dose regimen was safe and without toxicity.